These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 25820017)

  • 1. Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database.
    Kotze PG; Yamamoto T; Danese S; Suzuki Y; Teixeira FV; de Albuquerque IC; Saad-Hossne R; de Barcelos IF; da Silva RN; da Silva Kotze LM; Olandoski M; Sacchi M; Yamada A; Takeuchi K; Spinelli A
    J Crohns Colitis; 2015 Jul; 9(7):541-7. PubMed ID: 25820017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study.
    Preda CM; Fulger LE; Negreanu L; Manuc M; Sandra I; Diculescu MM
    Rev Esp Enferm Dig; 2016 Oct; 108(10):642-647. PubMed ID: 27651132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting the incidence of early endoscopic recurrence after ileocolonic resection for Crohn's disease: a multicentre observational study.
    de Barcelos IF; Kotze PG; Spinelli A; Suzuki Y; Teixeira FV; de Albuquerque IC; Saad-Hossne R; da Silva Kotze LM; Yamamoto T
    Colorectal Dis; 2017 Jan; 19(1):O39-O45. PubMed ID: 27943564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn's disease: an open-label, pilot study.
    Tursi A; Elisei W; Picchio M; Zampaletta C; Pelecca G; Faggiani R; Brandimarte G
    Tech Coloproctol; 2014 Nov; 18(11):1041-6. PubMed ID: 24915941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
    Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
    J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease.
    Kotze PG; Saab MP; Saab B; da Silva Kotze LM; Olandoski M; Pinheiro LV; Martinez CA; Ayrizono ML; Magro DO; Coy CS
    Dig Dis Sci; 2017 Feb; 62(2):456-464. PubMed ID: 27933472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
    Ponsioen CY; de Groof EJ; Eshuis EJ; Gardenbroek TJ; Bossuyt PMM; Hart A; Warusavitarne J; Buskens CJ; van Bodegraven AA; Brink MA; Consten ECJ; van Wagensveld BA; Rijk MCM; Crolla RMPH; Noomen CG; Houdijk APJ; Mallant RC; Boom M; Marsman WA; Stockmann HB; Mol B; de Groof AJ; Stokkers PC; D'Haens GR; Bemelman WA;
    Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):785-792. PubMed ID: 28838644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
    Cosnes J; Sokol H; Bourrier A; Nion-Larmurier I; Wisniewski A; Landman C; Marteau P; Beaugerie L; Perez K; Seksik P
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1102-1113. PubMed ID: 27666569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study.
    Papamichael K; Archavlis E; Lariou C; Mantzaris GJ
    J Crohns Colitis; 2012 Oct; 6(9):924-31. PubMed ID: 22424843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study.
    Armuzzi A; Felice C; Papa A; Marzo M; Pugliese D; Andrisani G; Federico F; De Vitis I; Rapaccini GL; Guidi L
    J Crohns Colitis; 2013 Dec; 7(12):e623-9. PubMed ID: 23810678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn's disease patients: a retrospective multicenter study.
    Na JE; Park YE; Park J; Kim TO; Lee JH; Park SB; Kim S; Lee SB;
    BMC Gastroenterol; 2024 Sep; 24(1):306. PubMed ID: 39261766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).
    Sussman DA; Kubiliun N; Mulani PM; Chao J; Gillis CA; Yang M; Lu M; T Abreu M
    Inflamm Bowel Dis; 2012 Nov; 18(11):2043-55. PubMed ID: 22241679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn's Disease Recurrence.
    Collins M; Sarter H; Gower-Rousseau C; Koriche D; Libier L; Nachury M; Cortot A; Zerbib P; Blanc P; Desreumaux P; Colombel JF; Peyrin-Biroulet L; Pineton de Chambrun G
    J Crohns Colitis; 2017 Mar; 11(3):281-288. PubMed ID: 27578800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients.
    Aguas M; Bastida G; Cerrillo E; Beltrán B; Iborra M; Sánchez-Montes C; Muñoz F; Barrio J; Riestra S; Nos P
    World J Gastroenterol; 2012 Aug; 18(32):4391-8. PubMed ID: 22969204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
    Stevens TW; Haasnoot ML; D'Haens GR; Buskens CJ; de Groof EJ; Eshuis EJ; Gardenbroek TJ; Mol B; Stokkers PCF; Bemelman WA; Ponsioen CY;
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):900-907. PubMed ID: 32619413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.
    Varma P; Paul E; Huang C; Headon B; Sparrow MP
    Intern Med J; 2016 Jul; 46(7):798-804. PubMed ID: 26865349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease.
    Macaluso FS; Fries W; Privitera AC; Cappello M; Siringo S; Inserra G; Magnano A; Di Mitri R; Mocciaro F; Belluardo N; Scarpulla G; Magrì G; Trovatello A; Carroccio A; Genova S; Bertolami C; Vassallo R; Romano C; Citrano M; Accomando S; Ventimiglia M; Renna S; Orlando R; Rizzuto G; Porcari S; Ferracane C; Cottone M; Orlando A;
    J Crohns Colitis; 2019 Feb; 13(2):209-217. PubMed ID: 30295785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
    Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
    Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.